Intuitive Surgical (ISRG) And The Da Vinci Growth Story On Valuation

Intuitive Surgical (ISRG) is back in focus after publishing a large systematic review and meta-analysis of da Vinci robotic-assisted surgery outcomes across 13 benign conditions, covering more than 14 million procedures worldwide.

For context, Intuitive Surgical shares trade at US$353.24, with the stock down 10.2% on a 30 day share price basis and 37.1% year to date, while the 1 year total shareholder return is down 21.5% but still positive over 3 and 5 years. This suggests longer term holders have seen far less momentum fade than recent traders.

See how Intuitive Surgical fits within a broader robotics trend by comparing it with our hand picked 37 robotics and automation stocks that are also involved in surgical and automation technology.

The selloff has reset expectations around Intuitive Surgical, but not the strength of its da Vinci franchise. After this kind of pullback, investors may ask whether the current valuation offers more potential upside or downside risk for new buyers.

Most Popular Narrative: 26.1% Undervalued

On the most followed narrative, Intuitive Surgical’s fair value of $478.01 sits well above the last close at $353.24, which frames the recent drop as a valuation gap rather than a broken story.

Ongoing product innovation (including full launch of da Vinci 5, integrated force feedback, and digital/AI case insights), coupled with R&D to expand into adjacent specialties, enhances clinical outcomes and surgeon efficiency, supporting future procedure growth, higher system ASPs, and increased recurring instrument and accessory revenues.

Read the complete narrative.

Want to see what this narrative is really baking in for Intuitive Surgical? Revenue rising faster than procedures. Earnings climbing quicker than sales. And a rich future multiple that assumes hospitals keep choosing da Vinci for more complex workloads. Curious which exact growth, margin and valuation assumptions have to line up for that fair value of $478.01 to make sense.

Result: Fair Value of $478.01 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the story around Intuitive Surgical can change quickly if international hospital budgets tighten further, or if new robotic rivals capture more procedure share than expected.

Find out about the key risks to this Intuitive Surgical narrative.

Another View on Intuitive Surgical’s Valuation

There is a catch. While our DCF model suggests Intuitive Surgical is trading about 14.2% below its estimated fair value at $411.88, the current P/E of 39.8x sits above both the fair ratio of 35.4x and peer averages near the mid 20s. That points to real multiple risk if sentiment cools.

For a closer look at how this pricing gap could close in either direction, and what the numbers imply for future returns, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and reset expectations around Intuitive Surgical leaves you undecided, step into the data yourself and stress test the assumptions. To see the key upside factors that current holders are focused on, review the 3 key rewards

Looking for more investment ideas beyond Intuitive Surgical?

If Intuitive Surgical has sharpened your thinking, do not stop here. Put fresh ideas on your radar by using focused screeners built around clear fundamentals.

• Target resilience by running a filter for companies with stronger balance sheets and sturdier fundamentals through the list of solid balance sheet and fundamentals (24 results).
• Spot potential mispricings by scanning for businesses that combine quality metrics with compressed valuations using the 31 high quality undervalued stocks.
• Build a dependable income stream by zeroing in on higher yielding payers that still look defensible with the 6 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com